Quantcast
Channel: Stock Blog Hub » Allos Therapeutics Inc.
Browsing latest articles
Browse All 5 View Live

(SPPI) Spectrum Pharmaceuticals to Continue Cancer Study

Recently, Spectrum Pharmaceuticals Inc. (SPPI) announced that it will continue evaluating its cancer candidate belinostat based on the recommendation of the independent Data Monitoring Committee (DMC)....

View Article



(CELG) Celgene Corporation Wins Label Expansion for Istodax

Recently, the US Food and Drug Administration (FDA) delivered a boost to Celgene Corporation (CELG) by approving its cancer drug Istodax (romidepsin) for an additional indication. The US regulatory...

View Article

(AEM) Company News for November 4, 2011 – Corporate Summary

•    Allos Therapeutics (NASDAQ:ALTH) posted a Q3 loss of $0.11 per share, lower than the Zacks Consensus Estimate for a loss of $0.15 per share. Revenues for the quarter rose 73.2% year-over-year to...

View Article

(PFE) Pharma and Biotech Stock Outlook – August 2012 – Industry Outlook

The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November...

View Article

(ALTH) Spectrum Pharmaceuticals Extends Allos Therapeutics Buyout Offer

Recently, Allos Therapeutics Inc. (ALTH) and Spectrum Pharmaceuticals (SPPI) announced the extension of the offer period for the purchase of the entire outstanding common stock of the former. The offer...

View Article

Browsing latest articles
Browse All 5 View Live




Latest Images